Skip to main content

Psoriatic arthritis

From 1055 new polyarthralgia presentations, 88 (8.3%) Dx w/ psoriatic arthritis. PsA Dx assoc w/ a +FamHx ( OR 4.14), psoriasis (OR=78.94), erosions (OR=5.74), US +power Doppler (OR=7.11). Neg assoc w/ +RF (OR 0.03), +CCP (OR 0.06).
Oligoarticular PsA: FOREMOST Study Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence. Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular PsA: Results from the Ongoing FOREMOST Study
cancer search news magnify

Xeljanz Cancer Risks Detailed

MedPage Today
Dec 07, 2022

The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.

Tofacitinib at either 5 or 10 mg twice daily in the so-called ORAL

Read Article

Bimekizumab Efficacy in TNF-Refractory Psoriatic Arthritis

Dec 07, 2022

Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.

The BE COMPLETE study was a phase

Read Article

The Top 10 Research Priorities in Psoriatic Arthritis

Dec 06, 2022

A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA).

A series of surveys were initated by the British Psoriatic Arthritis Consortium (BritPACT) and funded by the James Lind Alliance (JLA

Read Article

Comparing Biosimilar Growth in the US, Germany, and Switzerland

Dec 05, 2022

The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe. This analysis of the uptake and price of biologic therapy in Germany, Switzerland and the United States suggest that anticompetitive practices in the US could allow

Read Article
MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus
Sleep Quality & PsA Abstract #0387 presented at #ACR22 attempted to shed light in this important quality of life determinant. 247 adult PsA patients were included in this study and their sleep quality was measured using the PSQI questionnaire.
Differences in Presentation and Outcomes of Early vs Late Onset PsA Dr. Petryna ( @DrPetryna) discusses abstract 0377 presented at #ACR22. Abstract 0377: Differences in Early-onset vs. Late-onset PsA: Data from the RESPONDIA and REGISPONSER Studies
Best of #ACR22 Day 2 in PSA -Efficacy and Safety Results from BE OPTIMAL in PsA -JAK inhibitors in rheumatic diseases -Who is the Winner? Switch vs Cycle in PsA -Women vs. Men: Response to Treatment in Seronegative Arthritis and more.
Topic Podcasts - PsA Part1 Best of PsA on Day 1 #ACR22
Are MDA criteria created equal in PsA? Dr. Rachel Tate ( @uptoTate ) reviews abstract #1496: Do Patients in MDA Report Low Disease Activity Regardless of Which of the MDA Criteria Are Met? Presented at #ACR22.

Pain in Psoriatic Arthritis

Nov 22, 2022

The prioritisation of pain, and its evaluation, is important in those with psoriatic arthritis, when the already incredibly heterogenous nature of the condition can complicate assessment. Whilst we lean towards all pain in PsA being nociceptive in nature, evidence suggests that a significant

Read Article
Differences in Presentation and Outcomes of Early vs Late Onset PsA Dr. Petryna ( @DrPetryna) discusses abstract 0377 presented at #ACR22. Abstract 0377: Differences in Early-onset vs. Late-onset PsA: Data from the RESPONDIA and REGISPONSER Studies
Patient Reported Outcomes in PsA Using Novel IL 17A Inhibitor Dr. Sims ( @DrCassySims) discusses abstract 0199 presented at #ACR22.
Sleep asleep

Sleep Quality & Psoriatic Arthritis

Nov 15, 2022

For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many. Psoriatic arthritis is associated with a number of sleep problems, including trouble falling and staying asleep, poor-quality sleep and feeling sleepy during the day. Clinical

Read Article
Best of

ACR Best Abstracts - Day 3

Nov 14, 2022

The last day was jammed with important reports and research including the late breaking abstracts. 


Read Article

The complexity of opioid use in spondyloarthritis

Nov 14, 2022

A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. Abstract 0402 is a retrospective study that looked at patients with psoriatic arthritis or ankylosing spondylitis in the

Read Article
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199
Pain in #psoriaticarthritis might not be all inflammatory.. In this study presented by Dr F Sunzini: 👉PsA pts w/⬆️FM scores had⬆️functional brain connectivity bet mid-post IC & thalamus, phgyrus & PFC consider nociplastic pain too & adjust mgt #ACR22 @RheumNow ABST#2256
BE OPTIMAL Study - Bimekizumab (IL-17A and IL-17F inhibitor) for treatment of PsA. Similar ACR 50 (~50%) response rates of Bimekizumab, adalimumab, and placebo (switched to BKZ at wk 16). ~60% PASI100 in BKZ #ACRBest Abs#L02 @RheumNow #ACR22
Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcomes sustained. No joint difference to ADA, skin slightly better @RheumNow #ACR22 Abstr#L02
A new murine model to study Pso and PsA! Immunodeficient mice NSG-SGM3 🐁 injected w/ serum & PBMCs from Pso and/or PsA pts = pro & arthritis (same phenotype than pts) Mice skin & synovia >effector memory CD8 T cell & < naïve #ACR22 @Rheumnow
#L02 #acr22 @rheumnow Bimekizumab ph3 in PsA: meaningful clinical improvement, improved mTSS, no new safety signals. Wk 52 ACR50: 53.0% PBO/BKZ, 54.5% BKZ, 50.0% ADA; MDA 53.7% PBO/BKZ, 55.0% BKZ, 52.9% ADA . mTSS change from baseline ≤0.5): 87.3% PBO/BKZ, 89.3% BKZ, 94.1% ADA